PREVENTION OF INTRAVENTRICULAR HAEMORRHAGE IN PRETERM INFANTS BY PHENOBARBITONE. A Controlled Trial

StevenM Donn, DietrichW Roloff, Gary William Goldstein

Research output: Contribution to journalArticle

Abstract

Sixty infants with birth-weights less than 1500 g and who were less than 6 h old were randomly assigned to a group given phenobarbitone or a control group. Intravenous phenobarbitone was given in doses sufficient to achieve anticonvulsant serum levels within 12-18 h. Maintenance therapy was continued for one week. Periventricular/intraventricular haemorrhage (IVH) occurred in 133% (4/30) of the phenobarbitone group and in 46.7% (14/30) of the control group. The occurrence of risk factors related to IVH was similar in the two groups. Phenobarbitone may reduce the incidence of IVH in small preterm infants.

Original languageEnglish (US)
Pages (from-to)215-217
Number of pages3
JournalThe Lancet
Volume318
Issue number8240
DOIs
StatePublished - Aug 1 1981
Externally publishedYes

Fingerprint

Phenobarbital
Premature Infants
Hemorrhage
Control Groups
Birth Weight
Anticonvulsants
Incidence
Serum
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

PREVENTION OF INTRAVENTRICULAR HAEMORRHAGE IN PRETERM INFANTS BY PHENOBARBITONE. A Controlled Trial. / Donn, StevenM; Roloff, DietrichW; Goldstein, Gary William.

In: The Lancet, Vol. 318, No. 8240, 01.08.1981, p. 215-217.

Research output: Contribution to journalArticle

@article{f31e793cfaac4c079023ef83efa424aa,
title = "PREVENTION OF INTRAVENTRICULAR HAEMORRHAGE IN PRETERM INFANTS BY PHENOBARBITONE. A Controlled Trial",
abstract = "Sixty infants with birth-weights less than 1500 g and who were less than 6 h old were randomly assigned to a group given phenobarbitone or a control group. Intravenous phenobarbitone was given in doses sufficient to achieve anticonvulsant serum levels within 12-18 h. Maintenance therapy was continued for one week. Periventricular/intraventricular haemorrhage (IVH) occurred in 133{\%} (4/30) of the phenobarbitone group and in 46.7{\%} (14/30) of the control group. The occurrence of risk factors related to IVH was similar in the two groups. Phenobarbitone may reduce the incidence of IVH in small preterm infants.",
author = "StevenM Donn and DietrichW Roloff and Goldstein, {Gary William}",
year = "1981",
month = "8",
day = "1",
doi = "10.1016/S0140-6736(81)90470-0",
language = "English (US)",
volume = "318",
pages = "215--217",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8240",

}

TY - JOUR

T1 - PREVENTION OF INTRAVENTRICULAR HAEMORRHAGE IN PRETERM INFANTS BY PHENOBARBITONE. A Controlled Trial

AU - Donn, StevenM

AU - Roloff, DietrichW

AU - Goldstein, Gary William

PY - 1981/8/1

Y1 - 1981/8/1

N2 - Sixty infants with birth-weights less than 1500 g and who were less than 6 h old were randomly assigned to a group given phenobarbitone or a control group. Intravenous phenobarbitone was given in doses sufficient to achieve anticonvulsant serum levels within 12-18 h. Maintenance therapy was continued for one week. Periventricular/intraventricular haemorrhage (IVH) occurred in 133% (4/30) of the phenobarbitone group and in 46.7% (14/30) of the control group. The occurrence of risk factors related to IVH was similar in the two groups. Phenobarbitone may reduce the incidence of IVH in small preterm infants.

AB - Sixty infants with birth-weights less than 1500 g and who were less than 6 h old were randomly assigned to a group given phenobarbitone or a control group. Intravenous phenobarbitone was given in doses sufficient to achieve anticonvulsant serum levels within 12-18 h. Maintenance therapy was continued for one week. Periventricular/intraventricular haemorrhage (IVH) occurred in 133% (4/30) of the phenobarbitone group and in 46.7% (14/30) of the control group. The occurrence of risk factors related to IVH was similar in the two groups. Phenobarbitone may reduce the incidence of IVH in small preterm infants.

UR - http://www.scopus.com/inward/record.url?scp=0019506143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019506143&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(81)90470-0

DO - 10.1016/S0140-6736(81)90470-0

M3 - Article

VL - 318

SP - 215

EP - 217

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8240

ER -